There has been a flurry of antibody-drug conjugate (ADC) agreements in recent weeks, and today sees the inking of another deal involving Tokyo headquartered Ajinomoto Co Inc and US biotech, Exelixis.
Aji Bio-Pharma will add a flexible fill line, packaging and labelling equipment to its worldwide manufacturing network, in an investment worth upwards of $100m.